LIPIGON CHOOSES LINK MEDICAL AS THEIR CRO
Lipigon Pharmaceuticals AB have chosen LINK Medical, a Nordic contract research organization (CRO) for the planning and design of their clinical phase II study with Lipisense. The study aims to study safety and treatment effects in patients with severely elevated levels of the blood fat triglyceride.